How Blockchain may impact Clinical Trials

With blockchain being the world’s leading software platform for digital assets, the application of the technology in clinical trials has sparked discussion at PanAgora’s AI & Machine Learning in Clinical Trials Summit last month.

In a recent article published on Applied Clinical Trials , Moe Alsumidaie held an interview with Munther Baara (Head of New Clinical Paradigms at Pfizer) about his perspectives on how blockchain may impact clinical trials.

After describing blockchain technology, Munther Baara shared his insight on the use of blockchain in clinical trials:

“If clinical trials can employ blockchain technology, the aggregated data would be immediately available when a patient enrolls in a study, which can save time during screening. Research sites and sponsors would have the ability to view original and quality source documentation in real-time, which minimizes medical history data errors. Another benefit of using blockchain would be the ability for patients to better connect with individuals who have similar conditions (e.g., in rare disease populations), which can enhance trial referral potential. The drug supply chain could also be a great area where the industry can track investigational products all the way from inception to consumption, connect to the patients to gather medication adherence data, and facilitate drug accountability documentation. Sponsors can also use blockchain to register clinical trials and share study results with other researchers. Blockchain has the potential to be a game changer, as it would change the way we conduct business, not only in pharma but also globally across other industries.”


To read the full article visit